Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 13, 2021

Primary Completion Date

March 29, 2022

Study Completion Date

July 26, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

AZD1222

"Active substance: ChAdOx1 nCoV-19, a replicant-deficient simian adenoviral vector in the amount of 5 х 10\^10 particles (nominal) per dose (unit dose strength \> 0.7 × 10\^11 vp/mL).~Solution for intramuscular injection, supplied in vials in a carton box"

BIOLOGICAL

rAd26-S

"Component I (Dose 1) - (0.5 ml per dose) contains:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 10\^11 particles per dose (unit dose strength 1 × 10\^11 vp/0.5 mL) .~Solution for intramuscular injection, supplied in vials in containers"

Trial Locations (1)

15258

Tawam Hospital, Al Ain City

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

R-Pharm

INDUSTRY